Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
07. November 2024 16:05 ET
|
Evoke Pharma, Inc.
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52%...
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
09. September 2024 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
13. August 2024 08:00 ET
|
Evoke Pharma, Inc.
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills...
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
08. August 2024 08:30 ET
|
Evoke Pharma, Inc.
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug....
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
17. Juni 2024 08:30 ET
|
Evoke Pharma, Inc.
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA...
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
14. März 2024 16:05 ET
|
Evoke Pharma, Inc.
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 ...
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
27. November 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
14. November 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Third Quarter 2023 Financial Results
09. November 2023 08:30 ET
|
Evoke Pharma, Inc.
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year ...
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
31. Oktober 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...